Company

At CellTivity Scientific, we recognize that the limitations in point-of-care biopsy assessment largely contribute to delays in patient treatment. Our mission is to eliminate the uncertainty, inaccuracy, and delay of biopsy assessment and diagnosis, while maximizing diagnostic yield and sufficiency for next generation sequencing.

News
date
1
minute(s)
Category

Company

Leadership

At CellTivity Scientific, we recognize the limitations in point of care biopsy assessment contributes largely to the delay of patient’s treatment. Our mission is to eliminate the uncertainty, inaccuracy and delay of biopsy assessment and diagnosis, while maximizing Diagnostic Yield and Sufficiency for Next Generation Sequencing.

Interested in learning more about Van Gogh?

aquyre angular gradient

Empowering the proceduralist to improve patient outcomes through better diagnostic cancer sampling

Get in Touch